Breast Cancer Clinical Trial
— PILOfficial title:
Evaluating the Prevalence of Purpose-related Existential Distress Among 2 Clinical Populations Compared to a Normative Sample
Verified date | February 2024 |
Source | Allina Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
At present, there is no empirical data that specifies the likely prevalence of purpose in life disruption among various clinical populations. Between one-third and one-half of cancer survivors report some degree of existential distress during or after their treatment, but these findings are not specific to the domain of purpose in life. To address the aforementioned gap, we propose to conduct a survey study to determine the prevalence of purpose disruption in two clinical populations and determine if the prevalence of purpose disruption in these populations is different from that of a normative population.
Status | Enrolling by invitation |
Enrollment | 300 |
Est. completion date | August 31, 2024 |
Est. primary completion date | August 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18+ - Stage 1, 2, 3 cancer - Cancer types: breast cancer, non-Hodgkin's lymphoma; colorectal cancer - Receiving oncology services or treatment through AHCI - Have completed primary cancer treatment within the past 12 months - Able to communicate in English; - Able to see and read (with or without assistive devices); - Has access to a device (computer, phone, tablet) and an email address; - Access to an internet connection. - Has a known email address (in EPIC) and/or home telephone number - Adults who sustained a traumatic brain injury within the past 12 months. - Attending the 2022 MN State Fair Exclusion Criteria: - Have declined consent for use of medical records in research during admission to AH facility |
Country | Name | City | State |
---|---|---|---|
United States | Abbott Northwestern Hospital | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mary Radomski |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Purpose Status Question | A single forced-choice self-report screener question that we developed in order to characterize existential distress related to purpose in life (PSQ: "Related to living with purpose in life, right now I am: moving backwards; stalled; figuring it out; moving forward on a path"). | Through Study Completion, about 15 minutes | |
Secondary | Work and Adjustment Scale | A 5-item self-report questionnaire to characterize functioning related to work, social life, leisure, home management, and relationships. | Through Study Completion, about 15 minutes | |
Secondary | Meaning in Life Questionnaire | A 10-item questionnaire designed to measure 2 dimensions of meaning in life: Presence of Meaning (how much respondents feel their lives have meaning) and Search for Meaning (how much respondents strive to find meaning and understanding in their lives). | Through Study Completion, about 15 minutes | |
Secondary | Life Engagement Test | A 6-item self-report questionnaire that captures the extent to which a person engages in activities that are personally valued. | Through Study Completion, about 15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |